NasdaqGS:DFTXPharmaceuticals
How Investors May Respond To Definium Therapeutics (DFTX) Completing Phase III DT120 Enrollment In Depression
In early 2026, Definium Therapeutics, formerly Mind Medicine, gained fresh attention after completing enrollment for its Phase III Emerge trial of DT120 in major depressive disorder and advancing toward multiple pivotal readouts in generalized anxiety and depression later in the year.
This pipeline progress, alongside an early-stage program in autism spectrum disorder, is prompting investors to reassess how close Definium may be to shifting from pure R&D toward potential commercialization in...